CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study
Blood Advances
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study. // Blood Advances. – URL: https://www.sciencedirect.com/science/article/pii/S2473952926007688?dgcid=rss_sd_all
CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study. Blood Advances. https://www.sciencedirect.com/science/article/pii/S2473952926007688?dgcid=rss_sd_all
“CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study.” Blood Advances.
@article{article38438,
title = {CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study},
journal = {Blood Advances},
url = {https://www.sciencedirect.com/science/article/pii/S2473952926007688?dgcid=rss_sd_all}
}